DNDi and Abbott expand partnership to boost innovation for neglected tropical diseases
30 January 2012 | By Abbott
DNDi & Abbott have signed a four-year joint research & non-exclusive licensing agreement...
List view / Grid view
Abbott Laboratories is an American worldwide healthcare company. With headquarters in Lake Bluff, Illinois, it has 94,000 employees and operates in more than 150 countries.
The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; it eventually grew to also sell research-based drugs, medical devices, diagnostics, and nutritional products. It split off the research-based pharmaceuticals into Abbvie in 2013. In 2015, revenues were $20.4 billion.
Abbott has a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. The company’s in-vitro diagnostics business performs immunoassays and blood screening. Its medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other indicators of health. In 1985, the company developed the first HIV blood-screening test.
30 January 2012 | By Abbott
DNDi & Abbott have signed a four-year joint research & non-exclusive licensing agreement...
18 January 2012 | By Abbott
The U.S. FDA will begin implementing Abbott’s STARLIMS® software-based laboratory information management system...
12 December 2011 | By Abbott
Agreement calls for 50/50 global profit share for multiple new molecules...
8 December 2011 | By Abbott
Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial...
Abbott announced today it has received clearance from the U.S. Food and Drug Administration for a fully-automated 25-OH Vitamin D assay performed on its widely used ARCHITECT® laboratory testing platform.
28 November 2011 | By Abbott
Abbott announced that it will expand its existing agreement with GSK...
21 November 2011 | By Abbott
Abbott received approval from the U.S. FDA for a new Chagas in vitro diagnostic test...
15 November 2011 | By Abbott
Final results were presented today from the AIM-HIGH study, a National Heart, Lung and Blood Institute (NHLBI) study...
Abbott announced it has received CE Marking (Conformité Européenne) in the European Union to market a new, highly sensitive diagnostic test for detection of hepatitis B surface antigen (HBsAg). The test is performed on Abbott’s ARCHITECT® system. Hepatitis B is an inflammatory liver disease caused by the hepatitis B virus…
7 November 2011 | By Abbott
In ABILITY-1 Study Presented at ACR, More than Twice as Many Patients Treated with HUMIRA Met Primary Endpoint Compared to Placebo...
5 November 2011 | By Abbott
PREMIER Eight-Year and DE019 10-Year Data Presented at ACR 2011...
3 November 2011 | By Abbott
Abbott announced the company's schedule of key data presentations at the 23rd annual TCT scientific symposium...
1 November 2011 | By Abbott
FDA approval for the next-generation XIENCE PRIME™ Drug Eluting System...
24 October 2011 | By Abbott
New test based on FISH technology detects chromosomal abnormality to help predict prognosis of patients with AML...
19 October 2011 | By Abbott
Abbott plans to separate into two companies, one in diversified medical products & the other in research-based pharmaceuticals...